Suppr超能文献

感染,仍有很长的路要走。

Infection, Still a Long Way to Go.

作者信息

Kampouri Eleftheria, Croxatto Antony, Prod'hom Guy, Guery Benoit

机构信息

Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.

Institute of Microbiology, Department of Medical Laboratory and Pathology, University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.

出版信息

J Clin Med. 2021 Jan 20;10(3):389. doi: 10.3390/jcm10030389.

Abstract

is an increasingly common pathogen both within and outside the hospital and is responsible for a large clinical spectrum from asymptomatic carriage to complicated infection associated with a high mortality. While diagnostic methods have considerably progressed over the years, the optimal diagnostic algorithm is still debated and there is no single diagnostic test that can be used as a standalone test. More importantly, the heterogeneity in diagnostic practices between centers along with the lack of robust surveillance systems in all countries and an important degree of underdiagnosis due to lack of clinical suspicion in the community, hinder a more accurate evaluation of the burden of disease. Our improved understanding of the physiopathology of CDI has allowed some significant progress in the treatment of CDI, including a broader use of fidaxomicine, the use of fecal microbiota transplantation for multiples recurrences and newer approaches including antibodies, vaccines and new molecules, already developed or in the pipeline. However, the management of CDI recurrences and severe infections remain challenging and the main question remains: how to best target these often expensive treatments to the right population. In this review we discuss current diagnostic approaches, treatment and potential prevention strategies, with a special focus on recent advances in the field as well as areas of uncertainty and unmet needs and how to address them.

摘要

无论是在医院内还是医院外,它都是一种日益常见的病原体,可导致从无症状携带到伴有高死亡率的复杂感染等广泛的临床症状。尽管多年来诊断方法有了很大进展,但最佳诊断算法仍存在争议,且没有一种单一的诊断测试可作为独立测试使用。更重要的是,各中心诊断实践的异质性,以及所有国家缺乏强大的监测系统,再加上社区中因缺乏临床怀疑而导致的重要程度的诊断不足,阻碍了对疾病负担进行更准确的评估。我们对艰难梭菌感染(CDI)病理生理学的深入了解,已在CDI治疗方面取得了一些重大进展,包括更广泛地使用非达霉素、对多次复发使用粪便微生物群移植,以及已经开发或正在研发的包括抗体、疫苗和新分子在内的新方法。然而,CDI复发和严重感染的管理仍然具有挑战性,主要问题仍然是:如何以最佳方式将这些通常昂贵的治疗针对合适的人群。在本综述中,我们讨论了当前的诊断方法、治疗和潜在的预防策略,特别关注该领域的最新进展以及不确定性和未满足需求的领域,以及如何解决这些问题。

相似文献

1
Infection, Still a Long Way to Go.
J Clin Med. 2021 Jan 20;10(3):389. doi: 10.3390/jcm10030389.
2
Updated Management Guidelines for in Paediatrics.
Pathogens. 2020 Apr 16;9(4):291. doi: 10.3390/pathogens9040291.
3
: diagnosis and treatments.
BMJ. 2019 Aug 20;366:l4609. doi: 10.1136/bmj.l4609.
4
Diagnostic and therapy of severe Clostridioides difficile infections in the ICU.
Curr Opin Crit Care. 2020 Oct;26(5):450-458. doi: 10.1097/MCC.0000000000000753.
5
Current and future trends in clostridioides (clostridium) difficile infection management.
Anaerobe. 2019 Aug;58:95-102. doi: 10.1016/j.anaerobe.2019.04.010. Epub 2019 May 1.
6
Recent advances in the treatment of infection: the ever-changing guidelines.
Fac Rev. 2020 Nov 18;9:13. doi: 10.12703/b/9-13. eCollection 2020.
7
Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement.
Intensive Care Med. 2020 Feb;46(2):215-224. doi: 10.1007/s00134-019-05873-x. Epub 2020 Jan 14.
8
Updates in the epidemiology and management of candidemia and coinfection.
Expert Rev Anti Infect Ther. 2019 May;17(5):375-382. doi: 10.1080/14787210.2019.1608183. Epub 2019 May 3.
10
[Interpretation of group standard for infection diagnosis].
Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Jan 10;42(1):64-67. doi: 10.3760/cma.j.cn112338-20201026-01272.

引用本文的文献

2
European Practice for CDI Treatment.
Adv Exp Med Biol. 2024;1435:57-84. doi: 10.1007/978-3-031-42108-2_4.
3
Environmental approaches to controlling Clostridioides difficile infection in healthcare settings.
Antimicrob Resist Infect Control. 2023 Sep 7;12(1):94. doi: 10.1186/s13756-023-01295-z.
4
infection in patients with nonalcoholic fatty liver disease-current status.
World J Hepatol. 2023 Feb 27;15(2):208-215. doi: 10.4254/wjh.v15.i2.208.
5
The Urgent Threat of Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects.
Biomedicines. 2023 Feb 1;11(2):426. doi: 10.3390/biomedicines11020426.
6
Mouse models for bacterial enteropathogen infections: insights into the role of colonization resistance.
Gut Microbes. 2023 Jan-Dec;15(1):2172667. doi: 10.1080/19490976.2023.2172667.
7
Improving care for patients with infection: A clinical practice and healthcare systems perspective.
Front Med (Lausanne). 2023 Jan 12;9:1033417. doi: 10.3389/fmed.2022.1033417. eCollection 2022.
8
Antimicrobial Activity of Tannic Acid and Its Protective Effect on Mice against Clostridioides difficile.
Microbiol Spectr. 2023 Feb 14;11(1):e0261822. doi: 10.1128/spectrum.02618-22. Epub 2022 Dec 20.
10
Requirement of Peptidyl-Prolyl Cis/Trans isomerases and chaperones for cellular uptake of bacterial AB-type toxins.
Front Cell Infect Microbiol. 2022 Aug 4;12:938015. doi: 10.3389/fcimb.2022.938015. eCollection 2022.

本文引用的文献

1
Trends in U.S. Burden of Infection and Outcomes.
N Engl J Med. 2020 Apr 2;382(14):1320-1330. doi: 10.1056/NEJMoa1910215.
2
Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence.
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1053-1058. doi: 10.1007/s10096-019-03756-z. Epub 2020 Jan 11.
3
Environmental shedding of toxigenic Clostridioides difficile by asymptomatic carriers: A prospective observational study.
Clin Microbiol Infect. 2020 Aug;26(8):1052-1057. doi: 10.1016/j.cmi.2019.12.011. Epub 2020 Jan 3.
7
Toxigenic Clostridium difficile carriage in general practice: results of a laboratory-based cohort study.
Clin Microbiol Infect. 2019 May;25(5):588-594. doi: 10.1016/j.cmi.2018.12.024. Epub 2019 Jan 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验